ArticleMikrochimica acta2026
Electrochemical detection of miRNA-128 in Alzheimer's disease using (3-aminopropyl) triethoxysilane and citrate-capped green-synthesized silver nanoparticles.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The diagnostic method for Alzheimer’s disease (AD) is moving towards non-invasive approaches and miRNAs in biofluids are being considered as potential early biomarkers. Among all the miRNAs, the elevated levels of miRNA-128 in the serum may serve as potential diagnostic biomarker for AD. We report an electrochemical sensing platform based on a reusable fluorine-doped tin oxide (FTO) electrode, modified with citrate-capped silver nanoparticles (Ag-Cit NPs) synthesized using the Bryophyllum pinnatum leaf extract. Initially, the FTO were treated with (3-aminopropyl) triethoxysilane (APTES) to achieve the amine groups interaction with Ag-Cit NPs (Ag-Cit/APTES/FTO electrode). The biotinylated-cDNA (Btn-cDNA) was conjugated on Ag-Cit/APTES/FTO electrode with the help of streptavidin (SV) and the possible vacant electrode surface was blocked with the help of 6-mercapto-1-hexanol (MCH). The fabricated biosensing electrode (MCH/Btn-cDNA/SV/Ag-Cit/APTES/FTO) showed the low detection limit of 0.024 fM for miRNA-128 detection using electrochemical impedance spectroscopy. With the limit of quantification of 0.080 fM and a sensitivity of 402.48 Ω fM−1cm− 1, this nanoplatform achieved recoveries of 99% to 101.9%. The selective signal for miRNA-128 was obtained when compared with the mismatch and single mismatch miRNAs. Furthermore, the reliable performance in the real serum samples of AD patients, recommends this nano-sensor platform for future non-invasive detection tool in early diagnosis of AD.
Indexed as
Identifiers
42056645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.